← Back

Wire · operational-macro

FDA grants accelerated approval to neladalkib for previously treated locally advanced or ...

Published

17 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fda.gov →

◆ Verified

Fusion42 · 17 November 2026 · Fusion42 review

The FDA granted accelerated approval to neladalkib (Nelkarmi, Nuvalent, Inc.) for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who have previously received certain ALK tyrosine kinase inhibitors and chemotherapy, based on results from the ALKOVE-1 trial showing confirmed overall response rates.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your oncology biotech now faces a new competitor on FDA's fast track in ALK-positive lung cancer treatment. Shift clinical and market development to factor neladalkib’s entry disrupting existing second-line therapies.

◆ Coverage

1 source · 17 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvaloncologylung-canceralk-positivebiotech